Aerpio Pharmaceuticals, Inc. (ARPO)
(Delayed Data from NSDQ)
$1.04 USD
+0.01 (0.96%)
Updated May 3, 2019 04:13 PM ET
After-Market: $1.05 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Aadi Bioscience, Inc. [ARPO]
Reports for Purchase
Showing records 1 - 20 ( 29 total )
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Aadi Merger Transaction Brings a New Dawn; Upgrading to Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Price: 50.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
2020 Financial Results; Seeking Strategic Options; Reiterate Neutral Without PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Razuprotafib Glaucoma Phase 2 Data; Reiterate Neutral; Lowering PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Razuprotafib Phase 2 Glaucoma Trial Completes Enrollment; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results; Reiterate Neutral; Raising PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Glaucoma Trial Enrollment Starts; Reiterate Neutral; Raising PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Razuprotafib Enters COVID-19 Trial; Gossamer Deal Amended; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 10.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financial Results; Phase 2 Glaucoma Trial to Start in 2Q20; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Updated Topical AKB-9778 Glaucoma Data Presented; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Alternatives Being Explored; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 10.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Interim Phase 1b Data of Topical AKB-9778 in Healthy Subjects Presented; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 25.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 10.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b Trial in Glaucoma Initiated; Reiterate Neutral; Institute $1 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 10.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
ARVO 2019 Conference Highlights: Next-Generation Ophthalmology Therapeutics Emerge
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Price: 50.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Realignment Plan to Reduce Costs and Workforce; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
TIME-2b Trial Misses Primary Endpoint; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00
Company: Aadi Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Price: 10.00